BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Astria Therapeutics, Inc. (Nasdaq: ATXS) announce that the companies have entered into a definitive agreement under which BioCryst has agreed to acquire Astria, a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, for a mix of cash and stock representing an implied value of $13.00 per Astria share, and approximately $700 million in enterprise value. Astria’s lead product candidate navenibart is an injectable, long-acting, monoclonal antibody inhibitor of plasma kallikrein for hereditary angioedema (HAE) prophylaxis.
Read the full article: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile //
Source: https://www.businesswire.com/news/home/20251014246841/en/BioCryst-to-Acquire-Astria-Therapeutics-Strengthening-Presence-in-HAE-Transforming-Growth-Profile